portrait of smiling man stading in wooded areaportrait of smiling man stading in wooded areablue triangle graphic


Great Science
Deep Compassion
Real Impact

Working together to address addiction,
serious mental illness and cancer.

Discover Alkermes

Featured News

July 27, 2022

Alkermes plc Reports Second Quarter 2022 Financial Results

Read more

July 07, 2022

Alkermes Announces Results of Annual General Meeting of Shareholders

Read more

June 02, 2022

Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental ...

Read more

See all press releases

Smiling woman standing in hallway at Alkermes office.

Pride@Work

Our company possesses a profound power to help shape a more inclusive and equitable society for all. We recognize the importance of our role. See what our valued co-leaders have to say about their involvement with Pride@Work, our employee resource group for LGBTQ+ employees and allies.

Meet the co-leaders

Driven by Passion

Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.

Learn more about our culture

Man standing in lab coat with mask on in laboratory area at Alkermes.

Man sitting in front of green background at Alkermes office.

Inspiring Programs

Now in its sixth year, we are proud of the impact the Alkermes Inspiration Grants® program has made. Alkermes is currently reviewing this year's applications for creative and innovative programs that will make a difference for patient communities. Grant recipients will be announced later this year.

Visit the program page

Pipeline Preview


We seek to develop treatments that address unmet patient needs in complex and difficult-to-treat diseases in the areas of neuroscience and oncology. Our pipeline is comprised of clinical and preclinical candidates generated from our scientific platforms, including synaptic dysfunction in neuroscience and immune modulation in oncology.

View our pipeline

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Neuroscience

    • Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)

    • ALKS 2680 - Narcolepsy

  • Oncology

    • Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer

    • Nemvaleukin alfa - Mucosal Melanoma

*In combination with pembrolizumab
Neuroscience
Oncology

Careers

  We dare for progress every day. 
We take pride in our unique and compassionate spirit.
Our shared mission to make a real impact for others drives our purpose.
With collaboration at our core, we believe that anything is possible.

Working at Alkermes

Man with mask sitting in meeting talking to colleague at Alkermes.blue triangle graphic


We are driven by some of the most pressing health issues of our time to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases.